Saccharomyces boulardii Inhibits ERK1/2 Mitogen-activated Protein Kinase Activation Both in Vitro and in Vivo and Protects against Clostridium difficile Toxin A-induced Enteritis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Saccharomyces boulardii (Sb), a probiotic yeast, protects against intestinal injury and inflammation caused by a wide variety of enteric pathogens, including Clostridium difficile. Given the broad range of protective effects of Sb in multiple gastrointestinal disorders, we hypothesize that Sb modulates host signaling pathways involved in intestinal inflammatory responses. In this study, we found that Sb culture supernatant (SbS) inhibits interleukin-8 production induced by C. difficile toxin A or IL-1beta in human colonocyte NCM460 cells in a dose-dependent fashion. Furthermore, SbS inhibited IL-1beta and toxin A induced Erk1/2 and JNK/SAPK but not p38 activation in NCM460 cells. To test whether this inhibition also occurs in vivo, we used a previously established mouse ileal loop model. On its own, SbS had no significant effect on basal fluid secretion or intestinal histology. However, Erk1/2 activation was significantly inhibited by SbS in toxin A exposed mouse ileal mucosa. In control loops, toxin A increased fluid secretion (2.2-fold), histological score (3.3-fold), and levels of the chemokine KC (4.5-fold). SbS pretreatment completely normalized toxin A mediated fluid secretion (p < 0.01), and histopathologic changes (p < 0.01) and substantially inhibited toxin A-associated KC increases (p < 0.001). In summary, the probiotic yeast S. boulardii inhibits C. difficile toxin A-associated enteritis by blocking the activation of Erk1/2 MAP kinases. This study indicates a new mechanism whereby Sb protects against intestinal inflammation and supports the hypothesis that Sb modulates host inflammatory signaling pathways to exert its beneficial effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia
Bartlett, J. G., Chang, T. W., Gurwith, M., Gorbach, S. L., & Onderdonk, A. B. (1978) · New England Journal of Medicine · doi:10.1056/nejm197803092981003 · Cited by 1,374
Cited by
Mechanisms of probiotic actions – A review
Oelschlaeger, T. A. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2009.08.005 · Cited by 719
Review article: yeast as probiotics – Saccharomyces boulardii
CZERUCKA, D., PICHE, T., & RAMPAL, P. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03442.x · Cited by 587
Systematic review and meta-analysis of Saccharomyces boulardii in adult patients
McFarland, L. V. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i18.2202 · Cited by 545
Probiotics-host communication: Modulation of signaling pathways in the intestine
Thomas, C. M., & Versalovic, J. (2010) · Gut Microbes · doi:10.4161/gmic.1.3.11712 · Cited by 457
Using probiotics to improve swine gut health and nutrient utilization
Liao, S. F., & Nyachoti, M. (2017) · Animal Nutrition · doi:10.1016/j.aninu.2017.06.007 · Cited by 443
Kelesidis, T., & Pothoulakis, C. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11428502 · Cited by 377
“…cells [Buts, 2009; Dahan et al. 2003; Mumy et al. 2008; Pant et al. 2007; Sougioultzis et al. 2006] 4) Blocks activation of ERK1/2 and MAP kinases [Chen et al. 2006; Kyne et al. 2001; Mumy et al. 2008; Sougioultzis et al. 2006] 5) Decreases NO and inhibits production of inducible NOS…”
BackgroundInfluentialSelf-citationThe role of toxins in Clostridium difficile infection
Chandrasekaran, R., & Lacy, D. B. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux048 · Cited by 353
Modulatory Effects of Probiotics During Pathogenic Infections With Emphasis on Immune Regulation
Raheem, A., Liang, L., Zhang, G., & Cui, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616713 · Cited by 302
The Role of Probiotics and Prebiotics in Inducing Gut Immunity
Vieira, A. T., Teixeira, M. M., & Martins, F. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00445 · Cited by 273
Beneficial Effects of Probiotic and Food Borne Yeasts on Human Health
Moslehi-Jenabian, S., Lindegaard, L., & Jespersen, L. (2010) · Nutrients · doi:10.3390/nu2040449 · Cited by 237
Szajewska, H., & Kołodziej, M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13344 · Cited by 217
“boulardii-conditioned media inhibited IL8 production induced by either IL-1b or toxin A in a dosedependent fashion.(38) Additional mechanisms include competition for attachment sites and blocking C.”
BackgroundImmune responses to commensal and environmental microbes
Pamer, E. G. (2007) · Nature Immunology · doi:10.1038/ni1526 · Cited by 169
Review article: anti‐inflammatory mechanisms of action of Saccharomyces boulardii
POTHOULAKIS, C. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04102.x · Cited by 164
Self-citationKaźmierczak-Siedlecka, K., Ruszkowski, J., Fic, M., Folwarski, M., & Makarewicz, W. (2020) · Current Microbiology · doi:10.1007/s00284-020-02053-9 · Cited by 127
Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections
Czerucka, D., & Rampal, P. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i18.2188 · Cited by 116
Metadata
- Authors
- Chen, X., Kokkotou, E. G., Mustafa, N., Bhaskar, K. R., Sougioultzis, S., O'Brien, M., Pothoulakis, C., & Kelly, C. P.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-08
- Volume
- 281
- Issue
- 34
- Pages
- 24449-24454
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2034516137
- Cited by
- 157
- References
- 1
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.